Journal: Molecular Therapy Oncology

Article Title: Suppression of PARP1 enhances PTEN mRNA therapy in castration-resistant prostate cancer by glycolysis disruption

doi: 10.1016/j.omton.2026.201133

Figure Lengend Snippet: The antitumor effects of mPsiP@miLAND on PC-3 subcutaneous tumor model (A) Brief description of the experimental process and grouping information. (B) Tumor growth curves and (C) bodyweight changes of the treated animals during the entire study period. (D) Tumor weights, (E) serum biochemical indicators, and (F) relative mRNA expression of PARP1, recorded or analyzed at the end of the study. Seven indicators including creatine kinase (CK, U/liter), aspartate aminotransferase (AST, U/liter), alkaline phosphatase (ALP, U/liter), total protein (TP, g/liter), urea nitrogen (UREA, mmol/L), serum creatinine (CREA, mmol/L), and triglyceride (TG, mmol/L) were recorded. (G) Analysis of PI3K-Akt signaling, glycolysis, apoptosis, transcription, and translation in tumors after treatment. (H) The impacts of the formulations on tumor proliferation and apoptosis, as measured by Ki67 (top) and TUNEL (bottom) staining. ∗ p < 0.05, considered as statistically significant; ∗∗∗∗ p < 0.0001, each bar chart represents the mean ± SD.

Article Snippet: BstZ17I-HF endonuclease (R3594L), rCutSmart Buffer (B6004S), and HiScribe T7 ARCA mRNA in vitro transcription kit (E2060S) were purchased from NEB (MA, USA).

Techniques: Expressing, TUNEL Assay, Staining